The Role of the GP in the Management of Ambulatory Heart Failure
NCT ID: NCT05056649
Last Updated: 2023-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2022-10-01
2023-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation
NCT05097898
Optimizing Treatments for Heart Failure During Hospitalization
NCT05910437
Epidemiology and Prognostic of the Acute Heart Failure
NCT02880358
Evaluation and Support Care Process Within the Care Pathway of Heart Failure Patients
NCT04878263
Detecting EARLY Heart Failure in Greater Manchester
NCT05955456
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Heart Failure Patients with impaired ejection fraction
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Under 85 years of age
* Admitted to an Emergency department for cardiac decompensation
* Hospitalized following this decompensation
* Not deceased within one month of hospitalisation
* Whose sum of the doses of ACEI or ARB2 + BB + aldosterone antagonist is less than 50% of the dose required for this patient\* (definition in annex)
* Who did not object within one month of being informed
Exclusion Criteria
* Patient who does not have a general practitioner
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jean-Marc BOIVIN
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jean-Marc BOIVIN
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU of Nancy
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jean-Marc BOIVIN, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020PI049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.